Home LiteratureArticle Details
PMID: 18947395 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Validation Study

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.

Breast cancer research : BCR ·Vol. 10 ·No. 5 ·2008-00-00 ·Pages R89

Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM

Abstract

Manual interpretation of immunohistochemistry (IHC) is a subjective, time-consuming and variable process, with an inherent intra-observer and inter-observer variability. Automated image analysis approaches offer the possibility of developing rapid, uniform indicators of IHC staining. In the present article we describe the development of a novel approach for automatically quantifying oestrogen receptor (ER) and progesterone receptor (PR) protein expression assessed by IHC in primary breast cancer. Two cohorts of breast cancer patients (n = 743) were used in the study. Digital images of breast cancer tissue microarrays were captured using the Aperio ScanScope XT slide scanner (Aperio Technologies, Vista, CA, USA). Image analysis algorithms were developed using MatLab 7 (MathWorks, Apple Hill Drive, MA, USA). A fully automated nuclear algorithm was developed to discriminate tumour from normal tissue and to quantify ER and PR expression in both cohorts. Random forest clustering was employed to identify optimum thresholds for survival analysis. The accuracy of the nuclear algorithm was initially confirmed by a histopathologist, who validated the output in 18 representative images. In these 18 samples, an excellent correlation was evident between the results obtained by manual and automated analysis (Spearman's rho = 0.9, P < 0.001). Optimum thresholds for survival analysis were identified using random forest clustering. This revealed 7% positive tumour cells as the optimum threshold for the ER and 5% positive tumour cells for the PR. Moreover, a 7% cutoff level for the ER predicted a better response to tamoxifen than the currently used 10% threshold. Finally, linear regression was employed to demonstrate a more homogeneous pattern of expression for the ER (R = 0.860) than for the PR (R = 0.681). In summary, we present data on the automated quantification of the ER and the PR in 743 primary breast tumours using a novel unsupervised image analysis algorithm. This novel approach provides a useful tool for the quantification of biomarkers on tissue specimens, as well as for objective identification of appropriate cutoff thresholds for biomarker positivity. It also offers the potential to identify proteins with a homogeneous pattern of expression.

MeSH Terms
Adult Aged Aged, 80 and over Algorithms Antineoplastic Agents, Hormonal/therapeutic use Breast Neoplasms/chemistry,drug therapy,metabolism Carcinoma/chemistry,drug therapy,metabolism Cohort Studies Estrogen Receptor Modulators/therapeutic use Estrogens Female Humans Image Processing, Computer-Assisted/instrumentation,methods,statistics & numerical data Immunohistochemistry Middle Aged Neoplasm Proteins/analysis,biosynthesis Neoplasms, Hormone-Dependent/chemistry,diagnosis,drug therapy,metabolism Nuclear Proteins/analysis,biosynthesis Progesterone Receptors, Estrogen/analysis,biosynthesis Receptors, Progesterone/analysis,biosynthesis Tamoxifen/therapeutic use Treatment Outcome
Chemicals
Antineoplastic Agents, Hormonal Estrogen Receptor Modulators Estrogens Neoplasm Proteins Nuclear Proteins Receptors, Estrogen Receptors, Progesterone Tamoxifen Progesterone
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Rexhepaj Elton
UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Ireland.
Brennan Donal J
Holloway Peter
Kay Elaine W
McCann Amanda H
Landberg Goran
Duffy Michael J
Jirstrom Karin
Gallagher William M
References (33)
33 references, click to expand
  1. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray.
    Am J Clin Pathol. 2002 May;117(5):723-8 PMID: 12090420
  2. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.
    Am J Clin Pathol. 2005 Jan;123(1):21-7 PMID: 15762276
  3. Automated subcellular localization and quantification of protein expression in tissue microarrays.
    Nat Med. 2002 Nov;8(11):1323-7 PMID: 12389040
  4. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Clin Cancer Res. 2003 Jan;9(1 Pt 2):486S-94S PMID: 12538505
  5. Adjuvant endocrine therapy.
    Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):81-95 PMID: 14687599
  6. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods.
    Ann Diagn Pathol. 2004 Feb;8(1):23-7 PMID: 15129906
  7. Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures?
    Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):8-13 PMID: 15163012
  8. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    JAMA. 2006 Jun 7;295(21):2492-502 PMID: 16757721
  9. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.
    J Clin Oncol. 2006 Jul 1;24(19):3039-47 PMID: 16809728
  10. Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma.
    Mod Pathol. 2005 Apr;18(4):547-57 PMID: 15529185
  11. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
    Lancet. 2005 May 14-20;365(9472):1687-717 PMID: 15894097
  12. Global histone modification patterns predict risk of prostate cancer recurrence.
    Nature. 2005 Jun 30;435(7046):1262-6 PMID: 15988529
  13. Tissue microarrays: bridging the gap between research and the clinic.
    Expert Rev Proteomics. 2005 Jun;2(3):325-36 PMID: 16000080
  14. Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response.
    Expert Opin Biol Ther. 2005 Aug;5(8):1069-83 PMID: 16050784
  15. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
    Ann Oncol. 2005 Oct;16(10):1569-83 PMID: 16148022
  16. A human protein atlas for normal and cancer tissues based on antibody proteomics.
    Mol Cell Proteomics. 2005 Dec;4(12):1920-32 PMID: 16127175
  17. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.
    J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15 PMID: 16368942
  18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    N Engl J Med. 2005 Dec 29;353(26):2747-57 PMID: 16382061
  19. Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I.
    Histopathology. 2006 Oct;49(4):406-10 PMID: 16978204
  20. Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II.
    Histopathology. 2006 Oct;49(4):411-24 PMID: 16978205
  21. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Clin Cancer Res. 2006 Nov 1;12(21):6421-31 PMID: 17085655
  22. New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast.
    J Pathol. 2007 Apr;211(5):499-506 PMID: 17236182
  23. Quantitative analysis of estrogen receptor heterogeneity in breast cancer.
    Lab Invest. 2007 Jul;87(7):662-9 PMID: 17334408
  24. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.
    Cancer Genomics Proteomics. 2007 May-Jun;4(3):121-34 PMID: 17878516
  25. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma.
    Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):451-5 PMID: 18091390
  26. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
    Breast Cancer Res. 2008;10(1):R6 PMID: 18194560
  27. Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'.
    Breast Cancer Res. 2008;10(1):102 PMID: 18331621
  28. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
    Clin Cancer Res. 2008 May 1;14(9):2681-9 PMID: 18451232
  29. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.
    Breast Cancer Res Treat. 2008 Aug;110(3):417-26 PMID: 17912629
  30. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
    Clin Cancer Res. 2004 Aug 15;10(16):5367-74 PMID: 15328174
  31. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Lancet. 2005 Jan 1-7;365(9453):60-2 PMID: 15639680
  32. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
    Eur J Cancer. 2005 Jan;41(2):256-64 PMID: 15661551
  33. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists.
    Am J Surg Pathol. 2002 Jul;26(7):873-82 PMID: 12131154
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
Published
2008-00-00
Epub
2008-00-23
Pages
R89
Language
English
Region
England
NLM ID
100927353
PMCID
PMC2614526
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com